Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2013
10/03/2013WO2013061328A9 Methods of treating cancer
10/03/2013WO2012156527A9 Pharmaceutical composition having improved bioavailability
10/03/2013WO2003017945A3 Products containing highly unsaturated fatty acids for use by women and their children during stages of preconception, pregnancy and lactation/post-partum
10/03/2013US20130263297 Methods of treating cancer
10/03/2013US20130261592 Liquid pharmaceutical formulations of palonosetron
10/03/2013US20130261572 Patch
10/03/2013US20130261336 Methods and compositions for increasing the anaerobic working capacity in tissues
10/03/2013US20130261294 Novel Crystalline Forms Of An Antiviral Benzimidazole Compound
10/03/2013US20130261194 Functionalized Water-Soluble Polyphosphazenes and Uses Thereof as Modifiers of Biological Agents
10/03/2013US20130261193 Pheromone Compositions and Methods of Use
10/03/2013US20130261191 Use of essential oil compounds as histomonastat
10/03/2013US20130261189 Polyvinylpyrrolidone-containing acetaminophen liquid formulations
10/03/2013US20130261187 Compounds and methods for delivery of prostacyclin analogs
10/03/2013US20130261186 Methods of Treating Autism
10/03/2013US20130261185 Benzamide Derivatives As EP4 Receptor Agonists
10/03/2013US20130261184 Controlled release pharmaceutical compositions of pregabalin
10/03/2013US20130261183 Optimized nutritional formulations, methods for selection of tailored diets therefrom, and methods of use thereof
10/03/2013US20130261181 Molecules to Perfect HbA1c Levels
10/03/2013US20130261180 Clinical benefits of eicosapentaenoic acid in humans
10/03/2013US20130261179 Stabilised Prostaglandin Composition
10/03/2013US20130261177 Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest
10/03/2013US20130261169 Micro-RNA Family That Modulates Fibrosis and Uses Thereof
10/03/2013US20130261165 Prevention and treatment of diseases characterized by mesencephalic dopaminergic neuron cell death
10/03/2013US20130261163 Active compound combinations having insecticidal and acaricidal properties
10/03/2013US20130261161 Antiparasitic formulations
10/03/2013US20130261157 Novel multicomponent crystals made ([2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-carbamic acid ethyl ester and 2-[2-[(2,6-dichlorphenyl)-amino]-phenyl]-acetic acid
10/03/2013US20130261153 Use of ccr3-inhibitors
10/03/2013US20130261152 Orally effective methylphenidate extended release powder and aqueous suspension product
10/03/2013US20130261147 Composition for preventing or treating dementia
10/03/2013US20130261145 Pharmaceutical formulation containing gelling agent
10/03/2013US20130261144 Pharmaceutical Formulation Containing Gelling Agent
10/03/2013US20130261142 Compounds used for treating cancer and the use thereof
10/03/2013US20130261140 Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
10/03/2013US20130261137 Methods, Compounds and Compositions Relating to Activating a Latent Virus
10/03/2013US20130261136 Coffee extracts as ingredients of foods, drugs, cosmetics, dietary supplements, and biologics
10/03/2013US20130261135 Metalloenzyme inhibitor compounds
10/03/2013US20130261134 Mesylate salt forms of a potent hcv inhibitor
10/03/2013US20130261131 Pharmaceutical compositions and mentods for treatment of fungal infections
10/03/2013US20130261127 Composition for enhancing athletic performance
10/03/2013US20130261125 Indazole derivatives useful as erk inhibitors
10/03/2013US20130261120 Substituted n-(2-arylamino)aryl sulfonamide-containing combinations
10/03/2013US20130261116 Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5-disubstituted -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
10/03/2013US20130261114 Compounds useful as inhibitors of choline kinase
10/03/2013US20130261113 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
10/03/2013US20130261112 Cyclothiocarbamate Derivatives as Progesterone Receptor Modulators
10/03/2013US20130261109 Antitumor agent
10/03/2013US20130261108 Compositions and methods for modulating farnesoid x receptors
10/03/2013US20130261104 Methods of use of diazacarbazoles for treating cancer
10/03/2013US20130261103 Pyridazinones, method of making, and method of use thereof
10/03/2013US20130261101 Bicyclic azaheterocyclobenzylamines as pi3k inhibitors
10/03/2013US20130261097 Pharmaceutical composition and method for treating hypogonadism
10/03/2013US20130261096 Formulation For Hormonotherapy
10/03/2013US20130261095 Dexamethasone Formulations in a Biodegradable Material
10/03/2013US20130261092 Method of synergistically enhancing the therapeutic efficacy and safety of medication through a combination therapy
10/03/2013US20130261090 Method for treatment of sores in the oral cavity with a composition containing ultraviolet light-absorbing ingredients
10/03/2013US20130261087 Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses
10/03/2013US20130261085 Method of improving response to chemotherapy by administering a phospholipid together with chemotherapeutic agents, and formulations therefor
10/03/2013US20130261084 Method of improving response to chemotherapy by administering a phospholipid together with chemotherapeutic agents, and formulations therefor
10/03/2013US20130261082 Combination Therapy With Organic Arsenicals
10/03/2013US20130261079 High molecular weight heparosan polymers and methods of production and use thereof
10/03/2013US20130261078 Compositions of novel carbohydrate drug for treatment of human diseases
10/03/2013US20130261076 Administration of eritoran or pharmaceutically acceptable salts thereof to treat orthomyxovirus infections
10/03/2013US20130261075 Combination
10/03/2013US20130261074 Combination therapy for the treatment of cancer
10/03/2013US20130261072 Oligomer conjugates of heteropentacyclic nucleosides
10/03/2013US20130261068 Compositions and method for improving endothelial function and cardiovascular health
10/03/2013US20130261057 Methods for therapeutic treatment of benign prostatic hypertrophy (bph)
10/03/2013US20130261050 Oral combination therapy for treating hcv infection in specific patient sub-population
10/03/2013US20130261045 Green tea polyphenol alpha secretase enhancers and methods of use
10/03/2013US20130260453 Method for expression of small rna molecules within a cell
10/03/2013US20130259956 Pharmaceutical Kit for Treating Neuronal Damages
10/03/2013US20130259949 Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal
10/03/2013US20130259947 Oral metronidazole pharmaceutical compositions
10/03/2013US20130259941 Controlled release dosage forms
10/03/2013US20130259940 Tamper resistant dosage forms
10/03/2013US20130259939 Tamper resistant dosage forms
10/03/2013US20130259938 Tamper resistant dosage forms
10/03/2013US20130259936 Low-dose doxepin formulations and methods of making and using the same
10/03/2013US20130259935 Pharmaceutical compositions comprising glimepiride and polyethylene glycol castor oil
10/03/2013US20130259934 Implantable tizanidine compositions and methods of treatment thereof
10/03/2013US20130259932 Controlled release formulations of levodopa and uses thereof
10/03/2013US20130259931 Oral pharmaceutical compositions of nebivolol and process for their preparation
10/03/2013US20130259930 Compositions and Methods for Preventing and Treating Mucositis and Weight Loss
10/03/2013US20130259925 METHODS AND COMPOSITIONS TO TREAT CANCER USING BIFUNCTIONAL SRC 3 shRNA
10/03/2013US20130259921 Treatment Of Diabetic Patients With A Stent And An Adjunctive Drug Formulation
10/03/2013US20130259909 Benzoic Acid, Benzoic Acid Derivatives and Heteroaryl Carboxylic Acid Conjugates of Hydrocodone, Prodrugs, Methods of Making and Use Thereof
10/03/2013US20130259908 Micro-RNA Family that Modulates Fibrosis and Uses Thereof
10/03/2013US20130259906 Pharmaceutical composition comprising one or more fumaric acid esters
10/03/2013US20130259904 Prasugrel containing quickly released stable oral pharmaceutical compositions
10/03/2013US20130259897 Crystalline forms of (r)-3-[n-(3'-chlorobiphenyl-4-ylmethyl)-n'-(3-hydroxyisoxazole-5-carbonyl)hydrazino]-2-hydroxypropionic acid isopropyl ester
10/03/2013US20130259893 Food recipes for nourishing, maintaining and cultivating a variety of stem cells and a method for manufacturing the same
10/03/2013US20130259873 Methods for treating a tumor using an antibody that specifically binds hmw-maa
10/03/2013US20130259870 Galactomannan polysaccharide composition for the treatment of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
10/03/2013US20130259857 Methods for inhibiting fascin
10/03/2013US20130259856 Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
10/03/2013US20130259851 Use of prokaryotic sphingosine-1-phosphate lyases and of sphingosine-1-phosphate lyases lacking a transmembrane domain for treating hyperproliferative and other diseases
10/03/2013US20130259850 Compounds and method for reducing uric acid
10/03/2013US20130259832 Combinations of Hepatitis C Virus Inhibitors
10/03/2013US20130259831 3,5-Disubstituted and 3,5,7-Trisubstituted-3H-Oxazolo and 3H-Thiazolo[4,5-d]pyrimidin-2-one Compounds and Prodrugs Thereof
10/03/2013US20130259830 Crth2 modulators
1 ... 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 ... 7860